statistiche ricercatore

Continente	#
EU - Europa	577
NA - Nord America	564
AS - Asia	490
SA - Sud America	47
AF - Africa	17
Continente sconosciuto - Info sul continente non disponibili	1
Totale	1.696

Nazione	#
US - Stati Uniti d'America	553
SG - Singapore	167
CN - Cina	164
GB - Regno Unito	142
DE - Germania	110
SE - Svezia	71
IT - Italia	62
RU - Federazione Russa	45
IE - Irlanda	44
VN - Vietnam	38
UA - Ucraina	34
IN - India	32
TR - Turchia	28
BR - Brasile	26
FR - Francia	22
HK - Hong Kong	21
EU - Europa	20
KR - Corea	19
NL - Olanda	16
FI - Finlandia	15
CI - Costa d'Avorio	10
CO - Colombia	8
CA - Canada	6
GR - Grecia	6
JP - Giappone	6
AR - Argentina	5
UZ - Uzbekistan	5
CZ - Repubblica Ceca	3
MX - Messico	3
BE - Belgio	2
EC - Ecuador	2
EG - Egitto	2
IQ - Iraq	2
KE - Kenya	2
PE - Perù	2
PK - Pakistan	2
PY - Paraguay	2
AE - Emirati Arabi Uniti	1
AT - Austria	1
BS - Bahamas	1
CH - Svizzera	1
CV - Capo Verde	1
DK - Danimarca	1
GM - Gambi	1
ID - Indonesia	1
KH - Cambogia	1
KW - Kuwait	1
LT - Lituania	1
PH - Filippine	1
PL - Polonia	1
PS - Palestinian Territory	1
UY - Uruguay	1
VC - Saint Vincent e Grenadine	1
VE - Venezuela	1
XK - ???statistics.table.value.countryCode.XK???	1
ZA - Sudafrica	1
Totale	1.716

Nome	#
Long-Term Evaluation (Efficacy and Safety) of Infliximab in the Treatment of Persistently Active Juvenile Idiopathic Arthritis (JIA), Refractory to Standard Treatments	255
Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy	203
Juvenile idiopathic arthritis in adulthood in a tertiary reference centre	182
Skeletal mineralization in a prepubertal female population affected by juvenile idiopathic arthritis	181
Efficacy of a second TNFAlpha blocker when the first one failed in patients with juvenile idiopathic arthritis (JIA) treated with Infliximab, Etanercept and Adalimubab	180
Juvenile idiopathic arthritis in adulthood : evaluation of disease activity, damage and quality of life	171
Chronic Recurrent Multifocal Osteomyelitis (CRMO) : four cases treated with Aminobisphosphonate (Pamidronate)	165
Side Effects of Anti-Tnfα Therapy in Jia, in an Open Monocentric Prospective Study of 151 Patients	158
Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis : results of an open-label prospective study	157
Rituximab in juvenile idiopathic arthritis (JIA)non responsive to anti-TNF : experience of 14 patients treated	137
Totale	1.789

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	45	0	0	0	0	0	0	0	0	0	0	37	8
2021/2022	70	9	0	0	1	6	3	12	5	9	4	6	15
2022/2023	149	16	11	7	33	14	36	0	10	15	1	5	1
2023/2024	89	1	8	10	4	18	14	5	5	0	2	10	12
2024/2025	267	6	32	0	45	25	7	6	22	16	14	19	75
2025/2026	445	74	28	44	40	62	25	55	19	39	48	11	0
Totale													1.789

IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca